CARA THERAPEUTICS INC

NetDania - New 12 months Low: CARA THERAPEUTICS INC. - COMMON STOCK

21 Nov 2023 14:28:41 By NetDania Notify

NetDania - New 12 months Low: CARA THERAPEUTICS INC. - COMMON STOCK

14 Nov 2023 11:06:15 By NetDania Notify

Cara Therapeutics Reports Third Quarter 2023 Financial Results

13 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty

02 Nov 2023 07:00:45 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

25 Sep 2023 07:00:32 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Second Quarter 2023 Financial Results

07 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

03 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

02 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

18 May 2023 02:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports First Quarter 2023 Financial Results

15 May 2023 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

01 May 2023 07:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

10 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

14 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

06 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

21 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

08 Feb 2023 17:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

17 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire